Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.56 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 4/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.44 |
| ▸ | CDK2 | P24941 | 4/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30677864 | 0.80 | PDPK1 (0.58) | PDPK1POLA1CDK1CCNB1CCNA2 | |
| SCHEMBL9503859 | 0.79 | PDPK1 (0.56) | PDPK1POLA1CDK1CCNB1CCNA2 | |
| Methylguanine SCHEMBL231097 | 0.79 | CDK1 (0.69) | PDPK1CDK1CCNB1CCNA2CDK2 | |
| Methylguanine SCHEMBL29903462 | 0.79 | CDK1 (0.69) | PDPK1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6268751 | 0.76 | CDK1 (0.69) | XDHCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL4451634 | 0.76 | XDH (0.61) | PDPK1XDHDPP4KDM4ETMIGD3 | |
| SCHEMBL37384 | 0.75 | DPP4 (0.66) | PDPK1XDHDPP4KDM4ETMIGD3 | |
| SCHEMBL4525142 | 0.75 | PDPK1 (0.51) | PDPK1POLA1CDK1CCNB1CCNA2 | |
| SCHEMBL7437649 | 0.73 | PIN1 (0.71) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8719273 | 0.73 | DPP4 (0.63) | PDPK1XDHPOLA1DPP4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024925-A1 | Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof | ACURX PHARMACEUTICALS, LLC | 2022-01-27 | — | — | US | disclosed |
| EP-2475252-B1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | GLSYNTHESIS INC (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2475252-B1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | GLSYNTHESIS INC (US) | 2016-11-16 | — | — | EP | disclosed |
| CN-103788160-B | (2R, 5R)-5-phosphatidyl methoxy-2-(2-substituted adenines-9-base)-2,5-dihydrofuran nucleoside analog and its production and use | 郑州大学 | 2016-07-06 | — | — | CN | disclosed |
| US-8796292-B2 | Selective antibacterials for clostridium difficile infections | GLSYNTHESIS INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796292-B2 | Selective antibacterials for clostridium difficile infections | GLSYNTHESIS INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120232077-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | ACURX PHARMACEUTICALS, LLC | 2012-09-13 | — | — | US | disclosed |
| US-20120232077-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | ACURX PHARMACEUTICALS, LLC | 2012-09-13 | — | — | US | disclosed |
| EP-2475252-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | Glsynthesis Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011031935-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | GLSYNTHESIS INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232077-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | MRPL21, RPN2, ALPI | PDPK1 3556/4885XDH 355/4885POLA1 3253/4885 |
| US-20220024925-A1 | Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof | DUT, DCTD, TPMT | PDPK1 3185/4885XDH 75/4885POLA1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.